Homework: Decision Tree for Neurological and Musculoskeletal Disorders
Write a 1 to 2 pages summary paper that addresses the following:
a) Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.
b) Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
c) What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
d) Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.
Format your homework according to the following formatting requirements:
i) The answer should be typed, using Times New Roman font (size 12), double spaced, with one-inch margins on all sides.
ii) The response also includes a cover page containing the title of the homework, the student's name, the course title, and the date. The cover page is not included in the required page length.
iii) Also include a reference page. The Citations and references must follow APA format. The reference page is not included in the required page length.
Required Readings:
Rosenthal, L. D., & Burchum, J. R. (2018). Lehne's pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.
o Chapter 10, "Basic Principles of Neuropharmacology" (pp. 73-77)
o Chapter 11, "Physiology of the Peripheral Nervous System" (pp. 79-90)
o Chapter 12, "Muscarinic Agonists and Antagonists" (pp. 91-107)
o Chapter 13, "Adrenergic Agonists" (pp. 109-119)
o Chapter 14, "Adrenergic Antagonists" (pp. 121-132)
o Chapter 15, "Indirect-Acting Antiadrenergic Agents" (pp. 133-137)
o Chapter 16, "Introduction to Nervous System Pharmacology" (pp. 139-141)
o Chapter 17, "Drugs for Parkinson Disease" (pp. 143-158)
o Chapter 18, "Drugs for Alzheimer Disease" (pp. 159-166)
o Chapter 19, "Drugs for Epilepsy" (pp. 167-189)
o Chapter 20, "Drugs for Muscle Spasm and Spasticity" (pp. 191-201)
o Chapter 57, "Drug Therapy of Rheumatoid Arthritis" (pp. 629-641)
o Chapter 58, "Drug Therapy of Gout" (pp. 643-651)
o Chapter 59, "Drugs Affecting Calcium Levels and Bone Mineralization" (pp. 653-672)